Trial Profile
Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 01 Aug 2018 New trial record